Novo Nordisk (United States)

Recent papers from Novo Nordisk (United States)

1. Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW TrialDiabetes Obesity and Metabolism · 2026
2. Somapacitan Treatment in Children and Adolescents Born SGA: Two-Year Efficacy and Preference Over Daily GHThe Journal of Clinical Endocrinology & Metabolism · 2026
3. Development of Highly Efficient Lysosome‐Targeting Peptide Ligands for the Internalization of Extracellular ProteinsChemBioChem · 2026
4. Effect of coramitug on diuretic use in transthyretin amyloid cardiomyopathy (ATTR CM): a post-hoc analysis from a phase 2 randomised, placebo-controlled studyEuropean Heart Journal · 2026
5. Cardiovascular outcomes by baseline blood pressure control status in persons with type 2 diabetes at high cardiovascular risk treated with oral semaglutideEuropean Heart Journal · 2026
6. Prognostic value of high-sensitivity C-reactive protein versus low-density lipoprotein cholesterol for recurrent atherosclerotic cardiovascular disease events using US real-world dataEuropean Heart Journal · 2026
7. Prevalence, severity, and resolution of anemia in patients with infective endocarditis (ANIE study)European Heart Journal · 2026
8. Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetesAmerican Journal of Epidemiology · 2026
9. A Multi-Institutional Approach to Implementing Obesity Medicine Curricula in Undergraduate Medical Education: Feasibility, Acceptability, and Lessons LearnedInternational Medical Education · 2026
10. Association between elevated C-reactive protein and mortality, healthcare resource utilization and costs in patients with atherosclerotic cardiovascular disease and/or chronic kidney diseaseEuropean Heart Journal Open · 2026
11. From stochastic systems to governed intelligence: a neurosymbolic path for pharmaExpert Opinion on Drug Discovery · 2026
12. Assessment of changes in quality of life after thyroid surgery in older adults. A prospective studyFrontiers in Endocrinology · 2026
13. Nonclinical Development of Oligonucleotide-Based Therapeutics: Insights from an IQ DruSafe ONT Working Group SurveyNucleic Acid Therapeutics · 2026
14. Globally harmonized specifications: Implementing a patient-centric, enhanced control strategy – a meeting reportBiologicals · 2026
15. Machine Learning-Guided Discovery of Robust Conditions for Photochemical Nickel-Catalyzed Cysteine ArylationACS Catalysis · 2026
16. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trialEuropean Heart Journal · 2026
17. Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney DiseaseAdvances in Therapy · 2026
18. Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )Diabetes Obesity and Metabolism · 2026
19. Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseDiabetes Therapy · 2026
20. Mechanistic trade-offs between local and long-range signaling activity in natural and synthetic morphogensScience Advances · 2026